|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.08.26 - 22:09
|
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 46,044 shares of its common stock to 149 new non-executive employees with a grant date of August 3, 2026, under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Guardant, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Guardant, pursuant to Nasdaq Listing Rule 5635(c)(4).
One-third of the shares underlying each RSU award ve...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.07.26 - 22:09
|
Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance (Business Wire)
|
|
|
Second quarter 2026 revenue growth of 44% driven by strong performance in Oncology and Screening
Raises 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to 38%PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2026.
Second Quarter 2026 Financial Highlights
For the three-month period ended June 30, 2026, as compared to the same period of 2025:
Reported total revenue of $335.0 million, an increase of 44%, driven by:
Oncology revenue of $219.1 million, an increase of 38%, and approximately 104,000 oncology tests, an increase of 63%
Biopharma & Data revenue of $60.9 million, an increase of 9%
Screening revenue of $52.9 million, and approximately 66,000 Shield™ screening tests, compared to $14.8 million revenue and 16,000 tests in the prior year period
Generated non-GAAP gross margin of 67%, compared to 66% for the second quarter of 2025
Recent Operating Highli...
|
|
|
|
|
|
|
09.07.26 - 22:06
|
Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026 (Business Wire)
|
|
|
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including sc...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
